Ginkgo dvulopastnoho lystev ekstrakt | Memoplant tablets 40 mg, 30 pcs.

Special Price $24.25 Regular Price $33.00
In stock
SKU
BID473325
485 Reward Points will be used to purchase this product
Release form

Film-coated tablets
Release form

Film-coated tablets

Packing

30 pcs.

Pharmacological action

Memoplant is a phytopreparation, the active ingredient of which is ginkgo biloba leaf extract. Increases the body's resistance to hypoxia, especially brain tissue. It inhibits the development of traumatic or toxic cerebral edema. Improves cerebral and peripheral blood circulation, improves blood rheology.

Indications

- Disorders of the brain, including age-related, associated with impaired cerebral circulation, accompanied by the following symptoms: memory impairment, decreased ability to concentrate and intellectual abilities, dizziness, tinnitus, headache.

- Peripheral circulatory disorders: obliterating diseases of the arteries of the lower extremities with such characteristic symptoms as intermittent claudication, numbness and cooling of the feet, Raynaud's disease.

- Disorders of the inner ear, manifested by dizziness, erratic gait and tinnitus.

Contraindications

- Decreased blood coagulation.

- Erosive gastritis.

- Peptic ulcer of the stomach and duodenum in the acute phase.

- Acute cerebrovascular accident.

- Acute myocardial infarction.

- Children under 12 years of age (data on use are insufficient).

- Hypersensitivity to the drug.

Use during pregnancy and lactation

Due to lack of data, it is not recommended to use the drug Memoplant during pregnancy and lactation.

Special instructions

The patient should be informed that consultations with a doctor should be advised for frequent sensations of dizziness and tinnitus. In case of development of side effects, the use of the drug should be discontinued. The composition of the tablets includes lactose, therefore, the drug is not recommended for patients with congenital galactosemia, glucose or galactose malabsorption syndrome, or with congenital lactase deficiency.

Due to the lack of sufficient data, the drug should not be prescribed to children under the age of 12 years.

Composition of

In 1 film-coated tablet contains: dry standardized extract of leaves of ginkgo biloba (EGb 761) (35-67: 1, extractant - acetone 60%) 40 mg

Dosage and administration of

1-2 tablets 3 times / day are prescribed for the symptomatic treatment of cerebrovascular disorders. The course of treatment is at least 8 weeks.

In case of peripheral circulatory disorders, 1 tablet is prescribed 3 times / day or 2 tablets 2 times / day. The course of treatment is at least 6 weeks.

For vascular or involutional pathology of the inner ear, assign 1 tablet 3 times / day or 2 tablets 2 times / day. The course of treatment is 6-8 weeks.

Tablets should be taken without chewing, washed down with a small amount of water. The drug is taken regardless of the meal. If you missed the drug or if an insufficient quantity was taken, then the next dose should be carried out as indicated in the dosage regimen, without any changes.

Drug interaction

With the simultaneous use of Memoplant with anticoagulant drugs, the effect of the latter may be enhanced. The use of Memoplant is not recommended for patients who are constantly taking acetylsalicylic acid, anticoagulants (direct and indirect effects), as well as drugs that reduce blood coagulation.

Storage conditions

Store at a temperature of 15 ° to 25 РC.

Terms and conditions

without prescription

The shape of the tablets



Appointment

Vzrosl m

Indications

From Raynaud's disease, From disorders of cerebral circulation

Doctor Wilmar Schwabe GmbH & Ko. KG, Germany

Submit your review to Earn 10 Reward Points click here to login

Write Your Own Review
You're reviewing:Ginkgo dvulopastnoho lystev ekstrakt | Memoplant tablets 40 mg, 30 pcs.

 Job in company (10-20 minutes a day | 400 - 1200 USD)! 

We are looking for partners!

 If you have PayPal and you are ready to earn in our team - contact us: [email protected] 

Copyright © 2011-2024 Buy-Pharm, Inc. All rights reserved.